SCHEMBL876006

SCHEMBL876006

OCc1ccc(Oc2ccc(Cl)c(C(F)(F)F)c2)cc1Cl

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 1/20 0.44
PPARA Q07869 1/20 0.44
CHEK2 O96017 2/20 0.42
TRPV1 Q8NER1 1/20 0.42
IDO1 P14902 2/20 0.42
AR P10275 1/20 0.41
HTR2A P28223 3/20 0.41
SLC6A4 P31645 3/20 0.41
KCNH2 Q12809 3/20 0.41
SCN9A Q15858 3/20 0.40
NOTUM Q6P988 1/20 0.40
PLA2G7 Q13093 1/20 0.39
RAF1 P04049 2/20 0.39
HSP90AA1 P07900 1/20 0.39
KDR P35968 1/20 0.39
HDAC3 O15379 1/20 0.39
BRAF P15056 1/20 0.39
HDAC4 P56524 1/20 0.39
HDAC1 Q13547 1/20 0.39
HDAC7 Q8WUI4 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL877311 0.94 PPARG (0.46) PPARGPPARACHEK2TRPV1IDO1
SCHEMBL16199414 0.87 PPARG (0.41) PPARGPPARACHEK2TRPV1IDO1
SCHEMBL10244458 0.85 AR (0.56) ARPLA2G7KDR
SCHEMBL875664 0.83 IDO1 (0.50) PPARGPPARACHEK2IDO1AR
SCHEMBL29918384 0.83 IDO1 (0.50) PPARGPPARACHEK2IDO1AR
SCHEMBL15096323 0.82 HTR2A (0.45) ARHTR2ASLC6A4KCNH2
SCHEMBL875521 0.80 HTR2A (0.48) PPARGARHTR2ASLC6A4KCNH2
SCHEMBL15262126 0.80 KDR (0.41) PPARGPPARACHEK2TRPV1HTR2A
SCHEMBL876543 0.79 TLR8 (0.48) PPARGHTR2ASLC6A4KCNH2
SCHEMBL12806908 0.78 SCN9A (0.46) PPARGPPARAIDO1ARHTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140378487-A1 TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES GLAXO GROUP LTD (GB) 2014-12-25 US disclosed
US-20140378487-A1 TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES GLAXO GROUP LTD (GB) 2014-12-25 US disclosed
US-8871928-B2 Tricyclic compounds, preparation methods, and their uses GLAXO GROUP LIMITED (GB) 2014-10-28 US disclosed
US-8871928-B2 Tricyclic compounds, preparation methods, and their uses GLAXO GROUP LIMITED (GB) 2014-10-28 US disclosed
EP-2619203-A1 TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES Glaxo Group Limited (GB) 2013-07-31 EP disclosed
US-20130178488-A1 TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES GLAXO GROUP LIMITED (GB) 2013-07-11 US disclosed
US-20130178488-A1 TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES GLAXO GROUP LIMITED (GB) 2013-07-11 US disclosed
WO-2012037782-A1 TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES GLAXO GROUP LIMITED (GB) 2012-03-29 WO disclosed
WO-2012037782-A1 TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES GLAXO GROUP LIMITED (GB) 2012-03-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140378487-A1 TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES LIPG, PCSK9, ENPP2 PPARG 744/4885PPARA 643/4885CHEK2 3892/4885
US-20130178488-A1 TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES LIPG, PCSK9, ENPP2 PPARG 744/4885PPARA 643/4885CHEK2 3892/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.